Thomas J. Lynch Jr, MD, has been appointed the executive vice president and chief scientific officer for Bristol-Myers Squibb, effective March 16, 2017. He will succeed Francis Cuss, MB BChir, who will be retiring from the company. Lynch will simultaneously step down from the Board of Directors at Bristol-Myers Squibb, effective March 15, 2017.
Thomas J. Lynch Jr, MD
Thomas J. Lynch Jr, MD
Thomas J. Lynch Jr, MD, has been appointed the executive vice president and chief scientific officer for Bristol-Myers Squibb, effective March 16, 2017. He will succeed Francis Cuss, MB BChir, who will be retiring from the company, although Cuss will serve as an advisor for 3 months to facilitate a smooth transition. Lynch will simultaneously step down from the Board of Directors at Bristol-Myers Squibb, effective March 15, 2017.
“We are pleased to welcome Tom to the leadership team at Bristol-Myers Squibb,” said Giovanni Caforio, MD, chief executive officer and chairman designate of Bristol-Myers Squibb, in a press release. “Tom is an internationally recognized oncologist known for his leadership in the treatment of lung cancer and has made significant contributions to the field of targeted therapies throughout his career. Tom brings deep industry knowledge and a sophisticated understanding of the Bristol-Myers Squibb Research & Development program from his experience as a member of our board.”
Lynch has had a long and distinguished career in medicine, totaling more than 3 decades of medical, management, and leadership experience. He served as chairman and CEO of the Massachusetts General Physicians Organization, and as a board member for Massachusetts General Hospital from 2015 to 2017.
Lynch also served as the director of Yale Cancer Center, and was the Richard and Jonathan Sackler Professor of Internal Medicine at the Yale School of Medicine from 2009 to 2015. While at Massachusetts General Hospital in 2004, Lynch was part of the team credited with the discovery that certain genetic mutations in lung cancer patients caused therapies to work in certain patients. Lynch is also a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.
Notably, Lynch was recognized as a Giant of Cancer Care in 2013, for his innovative use of molecular testing for mutations in theEGFRgene to select patients who could benefit from targeted lung cancer therapies. He is internationally respected for his leadership in the development of novel therapies for the treatment of lung cancer, and is well-known as a pioneer in the field of personalized medicine.
“An award such as this depends upon team science. It depends upon people who are in the laboratory, looking at lung cancer from the very earliest of findings within a cell; it involves doctors taking care of patients in their office, bringing new therapies to the clinic. It involves the collaboration that all of us have,” Lynch said when accepting his Giants of Cancer Care award in 2013.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More